FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379284651> ?p ?o ?g. }

• W4379284651 endingPage "e13597" @default.
• W4379284651 startingPage "e13597" @default.
• W4379284651 abstract "e13597 Background: Immune checkpoint inhibitors have revolutionized the treatment landscape of malignancy. However, disproportionate enrollment among different races/ethnicities in global trials placed the generalizability in doubt. This meta-analysis aimed to estimate the relative efficacy of pembrolizumab between Asians and non-Asians with advanced cancers. Methods: A systematic review was conducted in PubMed, Cochrane Library, Embase, and Web of Science. The meta-analysis included phase 3 randomized controlled trials investigating pembrolizumab in advanced cancers with available subgroup analysis for Asians and non-Asians. The experimental strategies involved monotherapy versus standard-of-care (SOC) or best supportive care, an add-on to SOC, and combined with multikinase inhibitor versus standard chemotherapy, regardless of the setting. The primary and secondary effect measures were the mean difference (MD) in the natural logarithm (i.e., log) of the hazard ratio (HR) for overall survival (OS) and progression-free survival (PFS) between the two subgroups [MD=log(HR Asians )−log(HR Non-Asians )=log(HR Asians /HR Non-Asians )]. We used the random-effects meta-analysis to calculate the pooled ratio of HRs (i.e., exp(MD)) and implemented a meta-regression analysis to identify significant covariates. The heterogeneity among the selected studies was evaluated using the Chi-squared Q test and the I 2 statistic. Results: A total of 17 and 11 trials were selected in the meta-analysis for OS and PFS, respectively. These trials reported available subgroup results on Asians and non-Asians (patient numbers 2,732 [25.49%] and 7,000 [65.32%] for OS; 1,438 [22.50%] and 4,129 [64.61%] for PFS). The pooled ratio of HRs for OS was 0.87 (95% confidence interval [CI], 0.76−0.99; p = 0.0391; Chi-squared Q test Χ 2 = 20.84, p = 0.29; I 2 = 23.9%), favoring Asians, and no significant difference was found in PFS (the pooled ratio of HRs 0.93; 95% CI, 0.82−1.07; p = 0.2391; Chi-squared Q test Χ 2 = 7.37, p = 0.77; I 2 ≈ 0%). Both linear meta-regression analyses revealed an open-label design as an important covariate accounting for the observed difference, favoring non-Asians (estimated ratios of HR, 1.6318 for OS [95% CI, 1.1442-2.3273]; 1.3429 for PFS [95% CI, 1.0007−1.8020]). The sensitivity analysis showed that the percentage of subsequent treatment or post-progression programmed cell death 1 (PD-1)/ligand 1 (PD-L1) inhibitors had no significant impact. Conclusions: Asians receiving pembrolizumab for advanced cancers may have a superior OS advantage than non-Asians. Although the results warranted further exploration, this meta-analysis provided insight into clinical research design." @default.
• W4379284651 created "2023-06-05" @default.
• W4379284651 creator A5007140901 @default.
• W4379284651 creator A5009424735 @default.
• W4379284651 creator A5016301782 @default.
• W4379284651 creator A5020506159 @default.
• W4379284651 creator A5033582283 @default.
• W4379284651 creator A5048558239 @default.
• W4379284651 creator A5054458525 @default.
• W4379284651 creator A5063940560 @default.
• W4379284651 creator A5079843501 @default.
• W4379284651 date "2023-06-01" @default.
• W4379284651 modified "2023-10-17" @default.
• W4379284651 title "Different efficacy of pembrolizumab in overall survival between Asians and non-Asians with advanced cancers: A systematic review and meta-regression analysis." @default.
• W4379284651 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.e13597" @default.
• W4379284651 hasPublicationYear "2023" @default.
• W4379284651 type Work @default.
• W4379284651 citedByCount "0" @default.
• W4379284651 crossrefType "journal-article" @default.
• W4379284651 hasAuthorship W4379284651A5007140901 @default.
• W4379284651 hasAuthorship W4379284651A5009424735 @default.
• W4379284651 hasAuthorship W4379284651A5016301782 @default.
• W4379284651 hasAuthorship W4379284651A5020506159 @default.
• W4379284651 hasAuthorship W4379284651A5033582283 @default.
• W4379284651 hasAuthorship W4379284651A5048558239 @default.
• W4379284651 hasAuthorship W4379284651A5054458525 @default.
• W4379284651 hasAuthorship W4379284651A5063940560 @default.
• W4379284651 hasAuthorship W4379284651A5079843501 @default.
• W4379284651 hasConcept C121608353 @default.
• W4379284651 hasConcept C124936440 @default.
• W4379284651 hasConcept C126322002 @default.
• W4379284651 hasConcept C143998085 @default.
• W4379284651 hasConcept C168563851 @default.
• W4379284651 hasConcept C187960798 @default.
• W4379284651 hasConcept C207103383 @default.
• W4379284651 hasConcept C2777701055 @default.
• W4379284651 hasConcept C2780057760 @default.
• W4379284651 hasConcept C44249647 @default.
• W4379284651 hasConcept C50382708 @default.
• W4379284651 hasConcept C71924100 @default.
• W4379284651 hasConcept C95190672 @default.
• W4379284651 hasConceptScore W4379284651C121608353 @default.
• W4379284651 hasConceptScore W4379284651C124936440 @default.
• W4379284651 hasConceptScore W4379284651C126322002 @default.
• W4379284651 hasConceptScore W4379284651C143998085 @default.
• W4379284651 hasConceptScore W4379284651C168563851 @default.
• W4379284651 hasConceptScore W4379284651C187960798 @default.
• W4379284651 hasConceptScore W4379284651C207103383 @default.
• W4379284651 hasConceptScore W4379284651C2777701055 @default.
• W4379284651 hasConceptScore W4379284651C2780057760 @default.
• W4379284651 hasConceptScore W4379284651C44249647 @default.
• W4379284651 hasConceptScore W4379284651C50382708 @default.
• W4379284651 hasConceptScore W4379284651C71924100 @default.
• W4379284651 hasConceptScore W4379284651C95190672 @default.
• W4379284651 hasIssue "16_suppl" @default.
• W4379284651 hasLocation W43792846511 @default.
• W4379284651 hasOpenAccess W4379284651 @default.
• W4379284651 hasPrimaryLocation W43792846511 @default.
• W4379284651 hasRelatedWork W1234148476 @default.
• W4379284651 hasRelatedWork W1748720947 @default.
• W4379284651 hasRelatedWork W2056185445 @default.
• W4379284651 hasRelatedWork W2355800705 @default.
• W4379284651 hasRelatedWork W2555774950 @default.
• W4379284651 hasRelatedWork W2794116856 @default.
• W4379284651 hasRelatedWork W2799310318 @default.
• W4379284651 hasRelatedWork W3196188691 @default.
• W4379284651 hasRelatedWork W4248712168 @default.
• W4379284651 hasRelatedWork W4377238616 @default.
• W4379284651 hasVolume "41" @default.
• W4379284651 isParatext "false" @default.
• W4379284651 isRetracted "false" @default.
• W4379284651 workType "article" @default.